Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Updated clinical experience with MACOP-B.

P Klimo, J M Connors

    Seminars in Hematology
    |April 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    MACOP-B chemotherapy demonstrated high complete response rates in advanced diffuse large cell non-Hodgkin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis.

    Journal de medecine vasculaire·2022
    Same author

    Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups.

    AJNR. American journal of neuroradiology·2021
    Same author

    Cancer and thrombosis: new insights to an old problem.

    Journal de medecine vasculaire·2020
    Same author

    Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis.

    Journal de medecine vasculaire·2020
    Same author

    New progress in the treatment and prophylaxis of venous thrombo-embolism in cancer patients.

    Journal de medecine vasculaire·2020
    Same author

    Hodgkin lymphoma, treatment and thrombosis: a dangerous mix.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same journal

    Pain in SCD-Many mechanisms and mysteries.

    Seminars in hematology·2026
    Same journal

    The many facets of cardiopulmonary complications in sickle cell disease.

    Seminars in hematology·2026
    Same journal

    Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

    Seminars in hematology·2026
    Same journal

    Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

    Seminars in hematology·2026
    Same journal

    Telomeres biology disorders: the past, the present and the future.

    Seminars in hematology·2026
    Same journal

    Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

    Seminars in hematology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Hematology
    • Clinical Chemotherapy

    Background:

    • Advanced stage, diffuse, large cell non-Hodgkin's lymphoma presents a significant therapeutic challenge.
    • The MACOP-B chemotherapy regimen has been utilized for treating this patient population.

    Purpose of the Study:

    • To summarize the clinical experience and outcomes of MACOP-B chemotherapy in patients with advanced diffuse large cell non-Hodgkin's lymphoma.
    • To evaluate the efficacy, toxicity, and long-term results of the MACOP-B regimen.

    Main Methods:

    • Retrospective analysis of 125 patients with advanced diffuse large cell non-Hodgkin's lymphoma treated with MACOP-B chemotherapy.
    • Data collected on response rates (complete and partial), treatment failure, relapse, survival, and toxicity.
    • MACOP-B regimen includes methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin.

    Related Experiment Videos

    Main Results:

    • An 84% complete response rate and a 14.4% partial response rate were observed.
    • Overall toxicity was acceptable, with a 4.8% treatment-related mortality rate.
    • Mucocutaneous side effects were the most frequent toxicity; 10% incidence of nonfatal infections.

    Conclusions:

    • MACOP-B chemotherapy achieved results comparable to the best reported in the literature for advanced diffuse large cell non-Hodgkin's lymphoma.
    • The regimen demonstrated acceptable toxicity, shorter treatment duration, and reduced socioeconomic impact.
    • Further improvements in efficacy and toxicity are necessary; a new MACOP-B variant is under investigation.